NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function,.
Vaping After Quitting Smoking: A Potential Path to Lung Cancer scitechdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scitechdaily.com Daily Mail and Mail on Sunday newspapers.
Press Release: Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly